351324-52-2

Basic information

• Product Name: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole
• Synonyms: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole
• CAS NO: 351324-52-2
• Molecular Formula: C₁₀H₆F₃N₃O₂
• Molecular Weight: 257.1687496
• Mol File: 351324-52-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 359.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• PKA: 4.25±0.10(Predicted)
• CAS DataBase Reference: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole(351324-52-2)
• EPA Substance Registry System: 1-[4-Nitro-2-(trifluoroMethyl)phenyl]iMidazole(351324-52-2)

Safety Data

• Hazardous Substances Data: 351324-52-2(Hazardous Substances Data)

Usage

Chemical structure

A derivative of imidazole with a nitro and trifluoromethyl substituent on the phenyl ring.

Usage

Commonly used in pharmaceutical and agricultural industries.

Potential applications

a. Anti-inflammatory and analgesic agent.
b. Antifungal and antibacterial properties.
c. Building block in the synthesis of other pharmaceutical compounds.

Hazardous nature

Considered hazardous and may cause irritation to the skin, eyes, and respiratory system.

Handling precautions

Should be handled with caution to avoid exposure and potential health risks.

Upstream product

• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 
• 288-32-4 1H-imidazole 

Downstream Products

• 351324-53-3 4-(1H-imidazol-1-yl)-3-(trifluoromethyl)benzamine 
• 759419-73-3 N-(4-Imidazol-1-yl-3-trifluoromethyl-phenyl)-guanidine 

Relevant articles and documents

FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF

-

Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors

The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders.Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy.Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release.These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines.After examining a large number of analogs, N--4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.